ABSTRACT
Background Pre-existing comorbidities have been linked to SARS-CoV-2 infection but evidence is sparse on the importance and pattern of multimorbidity (2 or more conditions) and severity of infection indicated by hospitalisation or mortality. We aimed to use a multimorbidity index developed specifically for COVID-19 to investigate the association between multimorbidity and risk of severe SARS-CoV-2 infection.
Methods We used data from the UK Biobank linked to laboratory confirmed test results for SARS-CoV-2 infection and mortality data from Public Health England between March 16 and July 26, 2020. By reviewing the current literature on COVID-19 we derived a multimorbidity index including: 1) angina; 2) asthma; 3) atrial fibrillation; 4) cancer; 5) chronic kidney disease; 6) chronic obstructive pulmonary disease; 7) diabetes mellitus; 8) heart failure; 9) hypertension; 10) myocardial infarction; 11) peripheral vascular disease; 12) stroke. Adjusted logistic regression models were used to assess the association between multimorbidity and risk of severe SARS-CoV-2 infection (hospitalisation or death). Potential effect modifiers of the association were assessed: age, sex, ethnicity, deprivation, smoking status, body mass index, air pollution, 25‐hydroxyvitamin D, cardiorespiratory fitness, high sensitivity C-reactive protein.
Results Among 360,283 participants, the median age was 68 [range, 48-85] years, most were White (94.5%), and 1,706 had severe SARS-CoV-2 infection. The prevalence of multimorbidity was more than double in those with severe SARS-CoV-2 infection (25%) compared to those without (11%), and clusters of several multimorbidities were more common in those with severe SARS-CoV-2 infection. The most common clusters with severe SARS-CoV-2 infection were stroke with hypertension (79% of those with stroke had hypertension); diabetes and hypertension (72%); and chronic kidney disease and hypertension (68%). Multimorbidity was independently associated with a greater risk of severe SARS-CoV-2 infection (adjusted odds ratio 1.91 [95% confidence interval 1.70, 2.15] compared to no multimorbidity). The risk remained consistent across potential effect modifiers, except for greater risk among men.
Conclusion The risk of severe SARS-CoV-2 infection is higher in individuals with multimorbidity, indicating the need to target research and resources in people with SARS-CoV-2 infection and multimorbidity.
Competing Interest Statement
KK is chair for SAGE subgroup on ethnicity and COVID-19 and an independent member of SAGE.
Clinical Trial
Application Number: 36371
Funding Statement
This research was funded by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM), and the NIHR Leicester Biomedical Research Centre, and a grant from the UKRI-DHSC COVID-19 Rapid Response Rolling Call (MR/V020536/1). NGF acknowledges funding from the MRC Epidemiology Unit core support (MC_UU_12015/5), and NIHR Biomedical Research Centre Cambridge: Nutrition, Diet, and Lifestyle Research Theme (IS-BRC-1215-20014).The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants gave written informed consent prior data collection. UK Biobank has full ethical approval from the NHS National Research Ethics Service (16/NW/0274).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint senior authors
yc244{at}leicester.ac.uk
fz43{at}leicester.ac.uk
clg13{at}leicester.ac.uk
cr288{at}leicester.ac.uk
ty20{at}leicester.ac.uk
dk261{at}leicester.ac.uk
alex.rowlands{at}leicester.ac.uk
melanie.davies{at}uhl-tr.nhs.uk
nazrul.Islam{at}ndph.ox.ac.uk
sis11{at}leicester.ac.uk
nita.forouhi{at}mrc-epid.cam.ac.uk
kk22{at}leicester.ac.uk
Data Availability
The data that support the findings of this study are available from UK Biobank project site, subject to registration and application process. Further details can be found at https://www.ukbiobank.ac.uk. Data on patients with COVID-19 is from an updated database which has not been reported in other submissions. The UK Biobank protocol https://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf The statistical codes are available at GitHub yc244. https://github.com/yc244/Patterns-of-Multimorbidity-and-Risk-of-Severe-SARS-CoV-2-Infection-
https://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf
https://github.com/yc244/Patterns-of-Multimorbidity-and-Risk-of-Severe-SARS-CoV-2-Infection-
List of Abbreviations
- BMI
- Body mass index
- CI
- Confidence intervals
- CKD
- Chronic kidney disease
- COPD
- Chronic obstructive pulmonary disease
- CRP
- C-reactive protein
- eGFR
- Estimated Glomerular Filtration Rate
- IQR
- Interquartile range
- NHS
- National Health Service
- OR
- Odds ratio
- RR
- Relative risk
- UK
- United Kingdom
- WHO
- World Health Organization
- 25(OH)D
- 25-hydroxyvitamin D
